SEC Form 4 · accession 0001562180-17-000082
Akebia Therapeutics, Inc. · AKBA
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
Michel Dahan
Officer — SVP, Chief Business Officer
Period of report
Jan 1, 2017
Accepted (ET)
Jan 3, 2017 · 4:02 pm EST
Rule 10b5-1 plan
unknown — predates the checkbox
Issuer CIK
0001517022
Table I — non-derivative securities
| Security | Date | Code | Shares | Price | A/D | Owned after | D/I | Nature of ownership |
|---|---|---|---|---|---|---|---|---|
| Common StockF1 | Jan 1, 2017 | S | 1,629 | $10.4906 | D | 70,524 | D |
Table II — derivative securities
No Table II lines on this filing.
Explanation of responses
- F1Shares sold by reporting person to pay taxes in connection with the vesting of restricted stock pursuant to a December 23, 2013 award. Twenty-five percent of the shares vested on December 2, 2014, and the remaining shares vest in equal quarterly installments through October 1, 2017.